Psilocybin.
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • The US Drug Enforcement Agency (DEA) reverses its decision to schedule five psychedelic substances under the most restrictive class of drugs
  • Advocates and researchers pled their case in a DEA hearing, highlighting the potential medical and research benefits of the drugs
  • Following this hearing, the DEA withdrew its move to schedule the drugs and cancelled any further hearings
  • The news is a big win for US researchers who would have faced the brunt of the drug restrictions as well as higher costs
  • The drugs will remain illegal when used recreationally but will allow researchers to uncover potential medical treatments

The US Drug Enforcement Agency (DEA) has reversed its decision to schedule five psychedelic substances under the most restrictive class of drugs.

This category is usually reserved for substances that have no medical use and a high potential for abuse.

In January, the DEA made the move to schedule the drugs under this category, causing considerable public backlash due to the potential medical benefits.

This included a letter from a group of members of Congress urging the DEA to allow terminally ill patients the right to access psilocybin.

Advocates and researchers pled their case in a DEA hearing, highlighting the potential medical and research benefits of the drugs, one of which showed the potential to treat postpartum depression and treatment-resistant depression.

Following this hearing, the DEA withdrew its move to schedule the drugs and cancelled any further hearings.

It reasoned more updated scientific and medical evaluations were required from the Department of Health and Human Services.

The news is a big win for US researchers who would have faced the brunt of the drug restrictions as well as higher costs.

Psychedelic start-ups have been gaining traction recently, with billions invested into the industry and increasing acceptance from the US Food and Drug Administration.

The drugs will remain illegal when used recreationally but will allow researchers to uncover potential medical treatments.

More From The Market Online
AI concept

The great AI scare sell-off is still permeating Wall Street; a speculative blog from the not-so-distant future stands as the latest culprit

The ongoing tech sell-off in the United States, ironically driven by the larger AI thematic itself, continues to define
US and Aus flag

The XJO benefitted from geopolitical calm last week. New tariff fears perhaps feel more familiar

Last week, I wrote that the ASX200 was having a good week, where Australian investors were reacting to Australian earnings reports and how

Okay, so just where is gold heading? Experts say its nowhere near finishline yet

Leading industry, government and investment groups are still confident that the gold’s bull run is nowhere…
Koala share trading AI

The ASX 200 is up over 4% YTD. What EOY targets are floating around?

It’s been a pretty good year for the ASX200 so far, helped greatly by the ‘commodity supercycle’ narrative – which isn’t really a